MedTrace Logo

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

NCT05190575 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-07-27

No results posted yet for this study

Summary

TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for patients with CLDN18.2 positive previously treated unresectable advanced or metastatic Biliary Tract Cancer.

Conditions

  • Biliary Tract Neoplasms

Interventions

DRUG

TST001

TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.

Sponsors & Collaborators

  • Transcenta Holding Limited

    collaborator UNKNOWN

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Jia Fan · Shanghai Zhongshan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-14
Primary Completion
2023-05-06
Completion
2023-05-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05190575 on ClinicalTrials.gov